secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001140361-24-036938
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics reports Q2 2024 net loss of $12.4M; NAVIGATE interim readout on track for Dec 2024
--------------------------------------------------------------------------------

- NAVIGATE Phase 2b/3 trial of belapectin on track for interim top-line analysis in December 2024.
- Cash and equivalents of $25.6M at June 30, 2024; $10M line of credit from chairman available.
- Net loss for Q2 2024 was $12.4M ($0.20 per share) vs $9.2M ($0.15 per share) in Q2 2023.
- R&D expenses rose to $9.8M from $7.4M, driven by NAVIGATE trial costs.
- Cash runway expected to fund operations through approximately May 15, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124036938/0001140361-24-036938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124036938/ef20033852_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer